Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial
Lists
Only you see this
Abstract
The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study. We address these controversies and summarize active-immunization and passive-immunization experiments in nonhuman primates that support the initial finding.
BibTeX
@article{zollapazner2019revisiting,
author = {Susan Zolla‐Pazner and Peter B. Gilbert},
title = {{Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial}},
journal = {Journal of Virology},
year = {2019},
doi = {10.1128/jvi.00629-19},
}Loading related content...